1. Home
  2. FSSL vs ANL Comparison

FSSL vs ANL Comparison

Compare FSSL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FS Specialty

FSSL

FS Specialty

N/A

Current Price

$11.84

Market Cap

884.4M

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FSSL
ANL
Founded
2010
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
884.4M
998.8M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
FSSL
ANL
Price
$11.84
$10.80
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $29.50
AVG Volume (30 Days)
235.4K
★ 268.1K
Earning Date
01-01-0001
08-14-2026
Dividend Yield
★ 15.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
N/A
N/A
P/E Ratio
$9.70
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.75
$0.88
52 Week High
$14.49
$17.25

Technical Indicators

Market Signals
Indicator
FSSL
ANL
Relative Strength Index (RSI) 53.50 46.74
Support Level $11.78 $8.95
Resistance Level $11.91 $11.90
Average True Range (ATR) 0.25 0.99
MACD 0.03 0.25
Stochastic Oscillator 56.02 72.55

Price Performance

Historical Comparison
FSSL
ANL

About FSSL FS Specialty

FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing mainly in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest mainly in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: